We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sets Final Requirements for cIAI Clinical Trials
FDA Sets Final Requirements for cIAI Clinical Trials
March 12, 2015
Trials of therapies targeting complicated intra-abdominal infections should limit active comparators to drugs that are standard of care, the FDA says, and minimize the use of outside antibiotics as much as possible to produce clear, definitive trial results.